Search - tctmd.com

Displaying 41 - 60 of 270

Sort: Relevancy | Date

News Daily News

Top Structural Heart News of 2024

L.A. McKeown

December 29, 2024

News Opinion CV Team Dispatch

December 2024 Dispatch for the CV Team

L.A. McKeown

December 20, 2024

News Features

Reimbursement Issues Seem to Be Holding Renal Denervation Back

Todd Neale

December 19, 2024

Reverse Remodeling and Higher Stroke Volume With TEER: TRILUMINATE

Michael O'Riordan

December 03, 2024

News Conference News PCR London Valves 2024

Residual TR After Treating Mitral ViV Disease Linked to Worse Outcomes

Michael O'Riordan

November 26, 2024

News Conference News PCR London Valves 2024

Live Valve Cases Safe, With Outcomes Comparable to Trials and Practice

Michael O'Riordan

November 25, 2024

News Conference News TCT 2024

Percutaneous Mechanical Aspiration Promising for Right-Heart Infective Endocarditis

Caitlin E. Cox

November 08, 2024

News Conference News TCT 2024

TRISCEND II: Full Results a Win for TTVR in Severe Tricuspid Regurgitation

Michael O'Riordan

October 30, 2024

Presentation TCT 2024

TRISCEND II Trial: Transcatheter Valve Replacement vs. Optimal Medical Therapy for Severe Tricuspid Regurgitation

Presenter: Susheel Kodali

October 30, 2024

Presentation TCT 2024

TCT 978: A Computational Modeling Strategy to Study Transcatheter Tricuspid Valve Replacements in Patients With Severe Tricuspid Regurgitation

Presenter: Luis Rene Mata Quinonez

October 29, 2024

News Conference News TCT 2024

TRILUMINATE: More Patient Data Reassure on TEER’s Benefits for Severe TR

Michael O'Riordan

October 29, 2024

Presentation TCT 2024

TCT 967: Real World Outcomes of Patients With Severe Tricuspid Regurgitation Stratified by Clinical Sequelae

Presenter: Mahesh Madhavan

October 29, 2024

Presentation TCT 2024

TCT 970: Cost and Healthcare Utilization by Age, Sex, and Race in the Years Leading Up to a Severe or Clinically Significant Status for Patients With Tricuspid Regurgitation

Presenter: Colin Barker

October 29, 2024

Presentation TCT 2024

TCT 1343: TriClip Sandwich: EVOQUE Transcatheter Tricuspid Valve Replacement for Severe Tricuspid Regurgitation Following Single-Leaflet Device Attachment of Two TriClip Devices

Presenter: Bryan Traynor

October 28, 2024

Presentation TCT 2024

TCT 1384: Transcatheter Edge-to-Edge Repair for Severe Mitral Regurgitation in Tricuspid Atresia: A Case Report

Presenter: Alessandro Faggi

October 28, 2024

Presentation TCT 2024

Multicentric Randomized Evaluation of Transcatheter Edge-to-Edge Repair for Severe Isolated Tricuspid Regurgitation: The TRI-FR Trial: Evolution Over Time of Transthoracic Echocardiography Parameters

Presenter: Erwan Donal

October 27, 2024

News Opinion Editor's Corner TCT 2024

What’s Going to Be Big at TCT 2024?

Michael O'Riordan

October 17, 2024

News Daily News

Tricuspid TEER Continues to Offer Benefits Through 3 Years: TRILUMINATE

Caitlin E. Cox

September 12, 2024

News Conference News ESC 2024

Tri.Fr Trial Affirms Quality-of-Life Impact of Tricuspid TEER

Todd Neale

August 31, 2024

Presentation ESC 2024

Multicentric randomized evaluation of a Tricuspid valve Percutaneous Repair System (T-TEER) in the treatment of severe Tricuspid Regurgitation TRI.Fr

Presenter: Erwan Donal

August 31, 2024

Advertisement

Top Structural Heart News of 2024

December 2024 Dispatch for the CV Team

Reimbursement Issues Seem to Be Holding Renal Denervation Back

Reverse Remodeling and Higher Stroke Volume With TEER: TRILUMINATE

Residual TR After Treating Mitral ViV Disease Linked to Worse Outcomes

Live Valve Cases Safe, With Outcomes Comparable to Trials and Practice

Percutaneous Mechanical Aspiration Promising for Right-Heart Infective Endocarditis

TRISCEND II: Full Results a Win for TTVR in Severe Tricuspid Regurgitation

TRISCEND II Trial: Transcatheter Valve Replacement vs. Optimal Medical Therapy for Severe Tricuspid Regurgitation

TCT 978: A Computational Modeling Strategy to Study Transcatheter Tricuspid Valve Replacements in Patients With Severe Tricuspid Regurgitation

TRILUMINATE: More Patient Data Reassure on TEER’s Benefits for Severe TR

TCT 967: Real World Outcomes of Patients With Severe Tricuspid Regurgitation Stratified by Clinical Sequelae

TCT 970: Cost and Healthcare Utilization by Age, Sex, and Race in the Years Leading Up to a Severe or Clinically Significant Status for Patients With Tricuspid Regurgitation

TCT 1343: TriClip Sandwich: EVOQUE Transcatheter Tricuspid Valve Replacement for Severe Tricuspid Regurgitation Following Single-Leaflet Device Attachment of Two TriClip Devices

TCT 1384: Transcatheter Edge-to-Edge Repair for Severe Mitral Regurgitation in Tricuspid Atresia: A Case Report

Multicentric Randomized Evaluation of Transcatheter Edge-to-Edge Repair for Severe Isolated Tricuspid Regurgitation: The TRI-FR Trial: Evolution Over Time of Transthoracic Echocardiography Parameters

What’s Going to Be Big at TCT 2024?

Tricuspid TEER Continues to Offer Benefits Through 3 Years: TRILUMINATE

Tri.Fr Trial Affirms Quality-of-Life Impact of Tricuspid TEER

Multicentric randomized evaluation of a Tricuspid valve Percutaneous Repair System (T-TEER) in the treatment of severe Tricuspid Regurgitation TRI.Fr

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content